Vomiting News and Research

RSS
Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.
Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

New article finds no compelling evidence for withdrawing nitrous oxide from operating theaters

New article finds no compelling evidence for withdrawing nitrous oxide from operating theaters

U-M Food Allergy Center honors Mary Weiser's advocacy with renaming of center

U-M Food Allergy Center honors Mary Weiser's advocacy with renaming of center

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

Duke researchers reveal how bladder cells can eject UTI-causing bacteria

Duke researchers reveal how bladder cells can eject UTI-causing bacteria

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Scientists identify new molecules that destroy cancer cells, save healthy ones

Scientists identify new molecules that destroy cancer cells, save healthy ones

Transgender people at greater risk for eating disorders

Transgender people at greater risk for eating disorders

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Enhanced recovery program for patients undergoing colorectal operations speeds patients' recovery

Enhanced recovery program for patients undergoing colorectal operations speeds patients' recovery

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.